

## Selective glucocorticoid receptor modulation prevents and reverses non-alcoholic fatty liver disease in male mice

Lisa L. Koorneef, José K. van den Heuvel, Jan Kroon, Mariëtte R. Boon, Peter A.C. 't Hoen, Kristina M. Hettne, Nienke M. van de Velde, Kelsey B. Kolenbrander, Trea C.M. Streefland, Isabel M. Mol, Hetty C.M. Sips, Szymon M. Kielbasa, Hailiang Mei, Joseph K. Belanoff, Alberto M. Pereira, Maaike H. Oosterveer, Hazel Hunt, Patrick C.N. Rensen, Onno C. Meijer

*Endocrinology*  
Endocrine Society

Submitted: July 19, 2018  
Accepted: October 08, 2018  
First Online: October 12, 2018

Advance Articles are PDF versions of manuscripts that have been peer reviewed and accepted but not yet copyedited. The manuscripts are published online as soon as possible after acceptance and before the copyedited, typeset articles are published. They are posted "as is" (i.e., as submitted by the authors at the modification stage), and do not reflect editorial changes. No corrections/changes to the PDF manuscripts are accepted. Accordingly, there likely will be differences between the Advance Article manuscripts and the final, typeset articles. The manuscripts remain listed on the Advance Article page until the final, typeset articles are posted. At that point, the manuscripts are removed from the Advance Article page.

DISCLAIMER: These manuscripts are provided "as is" without warranty of any kind, either express or particular purpose, or non-infringement. Changes will be made to these manuscripts before publication. Review and/or use or reliance on these materials is at the discretion and risk of the reader/user. In no event shall the Endocrine Society be liable for damages of any kind arising references to, products or publications do not imply endorsement of that product or publication.

Selective GR modulator reverses liver steatosis

## Selective glucocorticoid receptor modulation prevents and reverses non-alcoholic fatty liver disease in male mice

Lisa L. Koorneef<sup>1,2\*</sup>, José K. van den Heuvel<sup>1,2\*</sup>, Jan Kroon<sup>1,2</sup>, Mariëtte R. Boon<sup>1,2</sup>, Peter A.C. 't Hoen<sup>3,4</sup>, Kristina M. Hettne<sup>3</sup>, Nienke M. van de Velde<sup>1,2</sup>, Kelsey B. Kolenbrander<sup>1,2</sup>, Trea C.M. Streefland<sup>1,2</sup>, Isabel M. Mol<sup>1,2</sup>, Hetty C.M. Sips<sup>1,2</sup>, Szymon M. Kielbasa<sup>5</sup>, Hailiang Mei<sup>6</sup>, Joseph K. Belanoff<sup>7</sup>, Alberto M. Pereira<sup>1</sup>, Maaïke H. Oosterveer<sup>8</sup>, Hazel Hunt<sup>7</sup>, Patrick C.N. Rensen<sup>1,2</sup>, Onno C. Meijer<sup>1,2</sup>

<sup>1</sup>*Department of Internal Medicine, Division of Endocrinology, Leiden University Medical Center, Albinusdreef 2, 2333ZA, Leiden, the Netherlands.*

<sup>2</sup>*Eindhoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Albinusdreef 2, 2333ZA, Leiden, the Netherlands.*

<sup>3</sup>*Department of Human Genetics, Leiden University Medical Center, Albinusdreef 2, 2333ZA, Leiden, the Netherlands.*

<sup>4</sup>*Centre for Molecular and Biomolecular Informatics, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center Nijmegen, Nijmegen, The Netherlands*

<sup>5</sup>*Bioinformatics Center for Expertise, Leiden University Medical Center, Albinusdreef 2, 2333ZA, Leiden, the Netherlands.*

<sup>6</sup>*Sequencing Analysis Support Core, Leiden University Medical Center, Albinusdreef 2, 2333ZA, Leiden, the Netherlands.*

<sup>7</sup>*Corcept Therapeutics, Menlo Park, CA 94025, California, USA.*

<sup>8</sup>*Departments of Pediatrics, Center for Liver Digestive and Metabolic Diseases, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ The Netherlands.*

### ORCID numbers:

0000-0002-1130-227X

Koorneef

Lisa L

0000-0001-5656-3898

Kroon

Jan

0000-0002-4182-7560

Hettne

Kristina M

0000-0002-1194-9866

Pereira

Alberto M

0000-0003-4117-7833

Oosterveer

Maaikje H

0000-0002-8455-4988

Rensen

Patrick CN

0000-0002-8394-6859

Meijer

Onno C

Received 19 July 2018. Accepted 08 October 2018.

\*Shared first author

List of abbreviations

NAFLD = non-alcoholic fatty liver disease; GC = glucocorticoid hormones; GR = glucocorticoid receptor; VLDL = very-low-density-lipoprotein; HFD = high-fat diet; LFD = low-fat diet; LCFA = long-chain fatty acids; HPA-axis = Hypothalamus-Pituitary-Adrenal-axis

Non-alcoholic fatty liver disease (NAFLD) medication is an unmet need. Glucocorticoid stress hormones (GC) drive fat metabolism in the liver, but both full blockade and full stimulation of GC signaling aggravate NAFLD pathology. We investigated the efficacy of selective glucocorticoid receptor (GR) modulator CORT118335, that recapitulates only a subset of GC actions, in reducing liver lipid accumulation in mice. Male C57BL/6J mice received low-fat diet, or high-fat diet mixed with vehicle or CORT118335. Livers were analyzed histologically and for genome-wide mRNA expression. Functionally, hepatic long-chain fatty acid (LCFA) composition was determined by gas chromatography. We determined very-low-density-lipoprotein (VLDL) production by treatment with a lipoprotein lipase inhibitor after which blood was collected to isolate radiolabeled VLDL particles and ApoB proteins. CORT118335 strongly prevented and reversed hepatic lipid accumulation. Liver transcriptome analysis showed increased expression of GR target genes involved in VLDL production. Accordingly, CORT118335 led to increased lipidation of VLDL particles, mimicking physiological GC action. Independent pathway analysis revealed that CORT118335 lacked induction of GC-responsive genes involved in cholesterol synthesis and LCFA uptake, which was indeed reflected in unaltered hepatic LCFA uptake *in vivo*. Our data thus reveal that the robust hepatic lipid lowering effect of CORT118335 is due to a unique combination of GR-dependent stimulation of lipid (VLDL) efflux from the liver, with a lack of stimulation of GR-dependent hepatic fatty acid uptake. Our findings firmly demonstrate the potential use of CORT118335 in the treatment of NAFLD and underscore the potential of selective glucocorticoid receptor modulation in metabolic disease.

## Introduction

Non-alcoholic fatty liver disease (NAFLD) is a prevalent condition (20-30% of the general population) with rising incidence due to the obesity pandemic, and to date long-term treatment options are restricted to weight loss surgery (1,2). NAFLD can advance to non-alcoholic steatohepatitis and further progress towards hepatic fibrosis, cirrhosis and hepatocellular carcinoma (3). NAFLD is primarily caused by an imbalance of hepatic energy influx and efflux. As glucocorticoid (GC) hormones have a strong impact on hepatic energy homeostasis, modulation of GC signaling seems an interesting treatment option (4).

GCs (predominantly cortisol in humans and corticosterone in rodents) are secreted by the adrenal cortex following a diurnal rhythm and during stress, mainly to support recruitment of energy reserves for the organism. These effects are mediated by the glucocorticoid receptor (GR), a member of the nuclear receptor superfamily (5). Among the widespread effects of GCs is the regulation of metabolic pathways in the liver, *i.e.* the stimulation of both the hepatic *influx* (uptake of free fatty acids and lipoproteins and via *de novo* lipogenesis) and *efflux* of lipids (via very-low-density-lipoprotein (VLDL) production) (6,7). As GCs control distinct pathways that induce *and* prevent steatosis, both excessive GC exposure and GR antagonism can promote development of liver steatosis and fibrosis (8,9).

Selective GR modulators combine GR agonism and antagonism that, upon binding to GR, induce unique receptor conformations that allow interaction with only subsets of downstream signaling pathways. Therapeutic potential has long been recognized for inflammatory disease, but unequivocal *in vivo* data remain limited, in particular in clinical settings (10-12). CORT118335 is a selective modulator that induces a profile of GR-coregulator interactions intermediate to full agonists and antagonists (13-15). In the present study, we demonstrate that CORT118335 fully prevents and reverses hepatic lipid accumulation in high-fat diet (HFD)-fed mice, highlighting the promise of selective GR modulation in metabolic disease.

## Materials and Methods

### Animal handling

The institutional ethics committee on animal care and experimentation at the Leiden University Medical Center (LUMC) approved all animal experiments that were conducted in Leiden (DEC13087 and DEC14245). Experiments were performed in 8-week old male C57Bl/6J mice (Charles River, France). Mice were individually housed in conventional cages with a 12:12 h light-dark cycle with *ad libitum* access to food and water. Throughout metabolic experiments, body weight was determined twice a week and body composition was monitored weekly using EchoMRI<sup>lm</sup>. To investigate metabolic effects of CORT118335, mice were randomized based on body weight to receive synthetic low-fat diet (LFD) or 10% fructose water with high-fat diet (HFD) (60% lard, Research Diets, USA) containing vehicle, CORT118335 (60 mg/kg/day), dexamethasone (1 mg/kg/day) or mifepristone (60 mg/kg/day). To evaluate efficacy of CORT118335 in a more severe NAFLD model with non-continuous drug administration, mice received a 16 weeks run-in HFD (45% lard, Research Diets, USA), after which mice were randomized based on body weight to a 3 week oral gavage treatment with vehicle or CORT118335. As peak drug levels are higher with oral administration, drug doses were decreased to 5 and 30 mg/kg/day; this study was carried out at RenaSci (Nottingham, United Kingdom). For RNA sequencing and determination of hepatic lipid composition, mice received LFD, HFD supplemented with vehicle, CORT118335 (60 mg/kg/day) or corticosterone (10 mg/kg/d) for two days (n=4 per group). The rationale for the higher dose of CORT118335 was that we hypothesized that part of its beneficial effects would depend on GR antagonism,

requiring full receptor occupancy, whereas the dose of 10 mg/kg/day for corticosterone suffices for substantial agonist effects. For all experiments, mice were sacrificed by cervical dislocation and perfused with ice-cold PBS after which tissues were collected for further analysis.

### **Indirect calorimetry**

At the start of the diet intervention, mice were transferred into fully automated metabolic cages for indirect calorimetry measurements (LabMaster System, TSE Systems, Germany). After 20 h of acclimatization, oxygen consumption ( $\dot{V}O_2$ ), carbon dioxide production ( $\dot{V}CO_2$ ) and caloric intake were measured for 5 consecutive days. Carbohydrate and fat oxidation rates, and total energy expenditure (EE) were calculated from  $\dot{V}O_2$  and  $\dot{V}CO_2$  as described previously (16).

### **Intravenous glucose tolerance test**

Mice were fasted for 6 h prior to the experiment. At  $t=0$ , blood was collected to measure basal plasma glucose, triglyceride and cholesterol levels. Next, a glucose bolus was injected (2 g/kg) and at  $t=5$ ,  $t=15$ ,  $t=30$ ,  $t=60$  and  $t=120$  minutes tail blood was collected, and plasma glucose levels were measured (Instruchemie, Netherlands).

### **Corticosterone and ACTH measurements**

Basal plasma corticosterone and ACTH levels were measured in blood that was collected within 60 or 120 seconds after the tail incision - *i.e.* before ACTH or corticosterone levels rise respectively - at AM (8:00) and PM (18:00). During the novelty stress test, at  $t=0$  a blood sample was collected after which mice were placed into a cage without bedding. After 10 minutes a blood sample was collected after which mice were placed back into their original home cage and additional stress-free blood samples were collected at  $t=30$ ,  $t=60$  and  $t=120$ . Plasma corticosterone levels were determined using  $^{125}I$  RIA kits (MP Biochemicals), with 25 ng/mL as lowest detection limit and coefficients of variation of less than 20%. Plasma ACTH levels were determined using the Double Antibody hACTH  $^{125}I$  RIA kit (MP Biomedical), with 7 pg/mL as lowest detection limit and coefficients of variation of less than 20%.

### **VLDL production measurement.**

Mice were fasted for 4 h and subsequently anaesthetized with 6.25 mg/kg acepromazine (Alfasan, the Netherlands), 6.25 mg/kg midazolam (Roche, the Netherlands) and 0.31 mg/kg fentanyl (Janssen-Cilag, the Netherlands). At  $t= -30$  minutes, 20  $\mu$ Ci Tran $^{35}S$  label (S-35 Methionine; MP Biomedicals, USA) was injected in the tail vein. At  $t=0$ , the LPL inhibitor Triton WR 1339 (0.5 g/kg) (Tyloxapol; Sigma-Aldrich, Netherlands) was additionally intravenously injected. At  $t=0$ , 15, 30, 60 and 90 minutes blood was collected from the tail vein and at  $t= 120$  mice were exsanguinated via the orbital sinus and sacrificed with an overdose of anaesthesia. VLDL was isolated from serum after density gradient ultracentrifugation at  $d < 1.006$  g/ml by aspiration (17). ApoB proteins were next isolated by precipitation with isopropanol and examined for incorporated  $^{35}S$  activity.

### **Hepatic lipid determination – Cobas C111 analyzer**

To extract lipids, HPLC grade isopropanol (Fisher, USA) was added to liver samples (1mL/100 mg of tissue). To dissolve lipids, tissues were homogenized, vortexed and incubated at 70 °C for 25 minutes. Tubes were re-vortexed to remove undissolved matter and the supernatant was assayed for triglycerides and cholesterol using the Cobas C111 clinical analyzer (Roche, USA) and associated reagents. The concentration of liver lipids was expressed as the concentration in the original tissue by multiplying by 10 as the liver sample was extracted in 10 volumes of isopropanol.

**Hepatic lipid determination- Bligh and Dyer**

Lipids were extracted from livers according to a modified protocol from Bligh and Dyer (18). Liver samples were homogenized in ice-cold methanol and lipids were extracted into an organic phase (methanol : chloroform = 3:1). After centrifugation, the lower, organic phase was dried and suspended in 2% Triton X-100. Hepatic triglyceride (TG) and total cholesterol (TC) concentrations were measured using commercial enzymatic kits (Roche Diagnostics, Netherlands). Liver lipids were reported per milligram of protein, as determined using the BCA protein assay kit (Thermo Scientific, Rockford, USA).

**Hepatic long-chain fatty acid determination**

Frozen liver tissue was homogenized in PBS and fatty acids were transmethylated to quantify fatty acid composition by gas chromatography using C17:0 as internal standard (19).

**Plasma lipid determination**

Blood was collected in paraxon-coated capillaries (Sigma-Aldrich, Netherlands) and triglyceride (TG), total cholesterol (TC), and phospholipid (PL) content was measured using commercially available enzymatic kits for TG, TC (Roche Diagnostics, Netherlands) and PL (Instruchemie, The Netherlands).

**Lipoprotein profiles**

To determine the distribution of cholesterol and triglycerides over the various lipoproteins, pooled plasma samples (n= 8 per pool) were used for fast performance liquid chromatography (FPLC). Plasma was injected onto a Superose 6 column (Äkta System; Amersham Pharmacia Biotech, USA) and eluted at a constant flow rate (50 µl/min) with PBS (pH 7.4). In the collected fractions, TG and TC content were measured as described above.

**RNA isolation, cDNA synthesis and real-time PCR**

Total RNA was isolated from frozen tissues utilizing Tripure RNA Isolation reagent (Roche Applied Science, the Netherlands). mRNA was reverse-transcribed and cDNA was used for quantitative real-time PCR using IQ SYBR-Green supermix (MyIQ thermal cycler, Bio-RAD CFX96). Melt curve analysis was included to assure a single PCR product and expression levels were normalized using the average expression of *Beta2-microglobulin* and *36b4* as housekeeping genes. Primer sequences are listed in Table S1.

**Histological analysis**

Gonadal white adipose tissue (gWAT) and liver tissue were fixed in 4% paraformaldehyde for 24 h and stored in 70% ethanol until further processing. Tissues were dehydrated, embedded into paraffin and were cut into 5 µm sections. Paraffin-waxed tissues were dewaxed and dehydrated before staining with Mayer's haematoxylin (Merck, the Netherlands) and eosin (Sigma-Aldrich, the Netherlands). Adipocyte size was quantified using ImageJ software (NIH,US (20)). For the F4/80 staining, sections were permeabilized (with 0.1% Tween/PBS), endogenous peroxidases were quenched and antigens were retrieved with proteinase-K before incubation with a primary F4/80 antibody (1/600; Serotec, Oxford, UK, RRID:AB\_2098196, [https://antibodyregistry.org/AB\\_2098196](https://antibodyregistry.org/AB_2098196)) overnight. Sections were incubated with a goat anti-rat secondary antibody (ImmPRESS<sup>TM</sup>, Vector Laboratories, UK) for 30 minutes, stained with Nova Red (Vector Laboratories, UK) and counterstained with Mayer's Haematoxylin. For oil red O staining, frozen hepatic tissue samples were cut in a degreased cryostat at -20°C at 10 µm. Sections were fixed with formalin, rinsed with isopropanol, stained with filtered oil red O working solution (3 g/L), counterstained with Mayer's Haematoxylin and mounted with Kaiser's glycerine jelly.

### RNA sequence analysis

Library construction and RNA sequencing were performed at BGI Tech Solutions CO., LTD (Hongkong, China). Briefly, isolated RNA was fragmented and first and second cDNA strands were synthesized. Adapters were ligated to A-tailed mRNA molecules with repaired ends, and cDNA fragments were enriched by PCR amplification and purified for 100bp paired-end sequencing with the HiSeq 4000 System (HiSeq 3000/4000 SBS Kit, Illumina). All RNA sequence files were processed using the BIOPET Gentrap pipeline version 0.6 developed at the LUMC ([http://biopet-docs.readthedocs.io/en/latest/releasenotes/release\\_notes\\_0.6.0/](http://biopet-docs.readthedocs.io/en/latest/releasenotes/release_notes_0.6.0/)). The pipeline includes the processes of quality control (with FastQC version 0.11.2), quality trimming (with sickle version 1.33), adapter clipping (with Cutadapt version 1.9.1), RNA sequence alignment (with GSNAP version 2014-12-23, with mm10 as reference genome), gene annotation (on 11-09-2015 information was downloaded from UCSC), read and base quantification (with htseq-count version 0.6.1p1 with settings of "--stranded no") and low quality read trimming. After running the BIOPET Gentrap pipeline, a differential expression analysis was performed with the edgeR package using R software (21). To correct for multiple testing, the Benjamini and Hochberg's False Discovery Rate (FDR) was put at 5%. Z- Scores data represent the distribution of normalized gene counts across all conditions for genes that showed significant differences between any of the groups. For pathway and mindmap analyses, the Euretos-Knowledge Platform was used (<http://Euretos.com/>). Euretos allows for semantic search for biologically interesting connections between genes, proteins, metabolites and drugs based on an underlying database of 176 integrated data sources (January 2017) [<http://www.euretos.com/files/EKPSources2017.pdf>]. Data from these databases were obtained in June 2017. Pathway analysis was performed by the use of the Fisher exact test for gene set enrichment.

### Statistical analysis

All data are expressed as mean  $\pm$  SEM. All p-values were two-tailed and  $p < 0.05$  was considered statistically significant. Data concerning one factor and two groups were analyzed with an independent sample T-test. When one factor and more than two groups were investigated, a one-way ANOVA with Fisher's post-hoc test was performed. When data concerned were both a factor and a time component, a mixed model analysis was performed in which time was modelled as factor with less than four time points and as covariate with four or more time points.

### Supplementary materials and data

Supplementary Tables and Figures can be found in an online depository (22).

### Results

#### **CORT118335 prevents obesity and hepatic accumulation of triglycerides and cholesterol**

To evaluate the effect of CORT118335 on obesity and related metabolic parameters, male C57Bl/6J mice received HFD supplemented with either vehicle (control) or CORT118335 for three weeks. CORT118335 significantly attenuated body weight gain (Fig. 1A), caused by a reduction of both fat mass (Fig. 1B, Fig. S.1A-C) and lean mass (Fig. 1C). Indirect calorimetry measurements in the first week of treatment showed that CORT118335 treatment reduced caloric intake while increasing energy expenditure and fat oxidation, but not carbohydrate oxidation (Fig. 1D-G). Oral glucose tolerance was improved upon CORT118335 treatment (Fig. 1H). In addition to the overall attenuation of HFD-induced adverse metabolic consequences, CORT118335 elicited a large reduction of hepatic triglycerides (-59%,  $p < 0.001$ ) and cholesterol (-14%,  $p = 0.02$ ), which was confirmed by oil red O staining (Fig. 1I, Fig. S.1D). Liver weight

was reduced after CORT118335 treatment (Fig. S.1E) and so was hepatic inflammation as determined by F4/80 immunostaining (Fig. S.1F).

### **CORT118335 reverses hepatic accumulation of triglycerides and cholesterol**

In view of the substantial change in liver lipid content after CORT118335 treatment, we next evaluated the capacity of CORT118335 to *reverse* the accumulation of hepatic lipids. Mice received either low-fat diet (LFD), HFD for three *or* six weeks, HFD with CORT118335 for six weeks ('prevention') or HFD for three weeks followed by HFD with CORT118335 ('reversal', Fig. 1J). CORT118335 treatment attenuated HFD-induced body weight gain, both in the prevention and in the reversal setting (Fig. 1K). CORT118335 effectively normalized hepatic triglycerides and cholesterol levels to those observed in LFD in both CORT118335 prevention and reversal treatment groups (Fig. 1L-M). Plasma cholesterol levels were increased in CORT118335-treated mice, which was mostly due to an increased high-density-lipoprotein fraction (Fig. S.2A-B). To investigate whether CORT118335 was also able to reverse liver steatosis in a more severe NAFLD model with non-continuous drug administration, mice received 45% HFD for 16 weeks after which they received CORT118335 treatment via oral gavage for three weeks. CORT118335 strongly and dose-dependently reduced liver triglycerides (-41% and -60%,  $p=0.09$  and  $p=0.09$  respectively, Fig. 1N) but not liver cholesterol (Fig. 1O).

To confirm that selective GR modulation is essential to improve liver phenotype, the full GR agonist dexamethasone and the full GR antagonist mifepristone were investigated. Both dexamethasone and mifepristone did not improve, and even aggravated, hepatic triglyceride accumulation (Fig. S.3A-C) - in spite of the fact that mifepristone significantly reduced food intake in this experiment (Fig. S.3D). This strongly supports the notion that CORT118335 effects on hepatic lipid content can be attributed to selective GR modulation.

### **CORT118335 stimulates hepatic VLDL-triglyceride production**

As liver steatosis develops as result of an imbalance in hepatic lipid metabolism pathways, expression of genes within these pathways was investigated in vehicle- and CORT118335-treated mice after three weeks of treatment. CORT118335 upregulated the expression of genes involved in VLDL production and secretion (i.e. *ApoB*, *Mttp*) but not the expression of genes involved in beta-oxidation (i.e., *Cpt1a*, *Acc2*) (Fig. 2A). Genes involved in fatty acid uptake (i.e. *Fabp1*, *Cd36*) were downregulated (Fig. 2A) as well as genes involved in *de novo* lipogenesis (*Srebp1c*, *Fasn*, *Dgat2*, *Acc1*, Fig 2A). Next, we investigated whether the CORT118335-induced upregulation of *Mttp* and *ApoB* expression was associated with increased VLDL production by assessing plasma triglyceride accumulation after inhibition of tissue lipoprotein lipase while labeling apolipoproteins with  $\text{Tran}^{35}\text{S}$ . In line with the transcriptional data, CORT118335 treatment led to increased plasma triglyceride accumulation over time (Fig. 2B-C). Increased hepatic VLDL output involved enhanced lipidation of VLDL particles rather than increased VLDL particle production, as the amount of triglycerides per apoB, but not plasma apoB, was significantly elevated in CORT118335-treated mice (Fig. 2D-E). As the MTP protein is responsible for the intracellular lipidation of apoB to generate VLDL (23), the upregulation of *Mttp* rather than *ApoB* mRNA appears to be predominantly involved in the biological effect of CORT118335 on VLDL-triglyceride production.

### **CORT118335 inhibits fatty acid uptake by the liver**

We next investigated whether the reduction of fatty acid transporter gene transcription after CORT118335 treatment (Fig 2A) was accompanied by functional alterations and how these effects were related to receptor (ant)agonism. To this end, long-chain fatty acids (LCFA) were



quantified in the livers of mice after 2 days of treatment with either LFD, HFD or HFD supplemented with CORT118335 or with corticosterone (Fig 2F). The essential fatty acid C18:2 $\omega$ 6 is a measure for hepatic LCFA uptake as it is exclusively diet-derived and cannot be synthesized *de novo*. CORT118335 tended to reduce hepatic C18:2 $\omega$ 6 content as compared to corticosterone-treated animals, suggesting that CORT118335 decreased hepatic fatty acid uptake. After six weeks of CORT118335 treatment, these effects were more pronounced as hepatic C18:2 $\omega$ 6 LCFA levels were fully normalized to LFD levels (Fig. S.4A). C20:4 $\omega$ 6 LCFA was absent from the diet (Fig. 2G) and therefore reflects elongation of lipids after uptake and *de novo* lipogenesis. Both corticosterone and CORT118335 significantly reduced C20:4 $\omega$ 6 content, although the effect of corticosterone was larger (Fig. 2F).

### **CORT118335 combines partial GR agonistic and antagonistic properties**

To identify the early beneficial transcriptional effects of CORT118335, we performed whole transcriptome analysis on livers of mice after two days of treatment with LFD, HFD, HFD supplemented with CORT118335 or with corticosterone. The overall gene expression profiles of corticosterone- and CORT118335-treated mice were comparable, as well as those of HFD and LFD groups (Fig. 3A). In a HFD condition, corticosterone regulated roughly twice as many genes as CORT118335 (Fig 3B). Most CORT118335-regulated genes were also regulated by corticosterone (Fig. 3C). Comparison between gene induction by corticosterone and CORT118335 indicated that, despite the higher dosage of CORT118335 and similar  $K_d$ , the latter acted as a partial GR agonist with an intrinsic efficacy of 0.65, as calculated from the slope of the regression line (Fig. 3D). Examples of partial agonistic actions of CORT118335 include the upregulation of classical GR target genes *Per1* and *Fkbp5*, and recently identified hepatic GR target genes *As3mt* and *Herpud1* (24) after CORT118335 treatment (Fig. S.5A). Other genes were strongly regulated by corticosterone but not, or to a much lesser extent by CORT118335 (Fig. 3D). Expression of GR target genes *Mt1*, *Mt2*, *Abil* and *Comt* (24) clearly demonstrated lack of agonism of the compound (Fig. S.5A). Partial agonism of CORT118335 on the GR was also evident from effects on *in vivo* Hypothalamus-Pituitary-Adrenal-axis (HPA-) dynamics, as the compound suppressed both basal and stress-induced endogenous corticosterone and ACTH plasma levels and reduced tissue weights of GC-sensitive thymus, adrenals and spleen (Fig. S.5B-D).

### **Corticosterone and CORT118335 differentially regulate lipid transport, cholesterol biosynthesis and cytokine signaling pathways**

As the beneficial effects of CORT118335 can most likely be attributed to a combination of both GR agonism (e.g. VLDL production) and antagonism (e.g. fatty acid transport), we performed pathway analyses on *shared* and *differentially* regulated genes by corticosterone and CORT118335. *Shared* upregulated genes (Fig. S.6A) were enriched for lipid, lipoprotein, glucose and glycogen metabolism pathways (Fig. S.7A). Further subdivision of the 'lipid metabolism' pathway showed that both corticosterone and CORT118335 upregulated gene expression for *de novo* lipogenesis and beta oxidation (Fig. S.6B). As expected, genes involved in VLDL production pathway, *Mttp* and *Apob*, were upregulated after both treatments (Fig. S.6C).

*Differentially* expressed genes between corticosterone and CORT118335 (n=349, Fig. 3B) showed significant enrichment of the 'Metabolism of Lipids and Lipoproteins' pathway' (Fig. 4A). The genes selectively upregulated by corticosterone were also enriched for lipid metabolism pathways (Fig. S.7B) and some genes in this pathway were likely directly regulated by the GR (*Fabp4* (25), *Cd36* (26-29) and *Nr1h4* (26,27,29-31)) (Fig. 4B). Several selectively

corticosterone-upregulated genes are associated with liver steatosis (*Cd36* (32-36), *Nr1h4* (36-38) and *Fabp4* (39,40)) (Fig. 4B-C), and lipid transport (*Cd36* (41) and *Fabp4* (42)). Of note, corticosterone, but not CORT118335, also upregulated genes of cholesterol biosynthesis pathways (Fig. S.7B). Among those differently regulated genes was *Hmgcs1*, which encodes for one of the rate-limiting enzymes in cholesterol biosynthesis and is a direct target gene of the GR (Fig. S.7C) (26,27,29,30). To investigate the effects of CORT118335 on GR-mediated transrepression mechanisms, pathway analysis was performed on genes that were specifically downregulated by corticosterone but not by CORT118335. This revealed that corticosterone but not CORT118335 downregulated 'Cytokine Signaling in Immune System' and 'Jak-Stat signaling' pathways (Fig. S.7D).

## Discussion

Our data firmly demonstrate that CORT118335 prevents and reverses liver steatosis in mice. In order to support daily activity and adaptation to stress, endogenous GC are known to increase the flux of hepatic lipids by increasing VLDL production as well as lipid uptake (43,44), effects that are predominantly GR-mediated (Fig. 5) [18]. CORT118335 selectively recapitulates the lipid outflow component via GR agonism, while lacking lipid uptake promoting activities, altogether confirming its selective GR modulatory profile (Fig. 5) (13). Our transcriptome analysis, early during intervention, showed predominant partial GR agonism in the liver, with some notable exceptions that are likely – and fortuitously – linked to prevention of hepatic lipid accumulation. The major factors involved in reduced hepatic lipid accumulation upon CORT118335 treatment are increased VLDL-triglyceride production, reduced LCFA uptake and potentially also increased whole-body fatty acid oxidation, as increased fatty acid oxidation in extra-hepatic tissues may reduce lipid flux towards the liver. Additionally, reduced food intake, adiposity and *de novo* lipogenesis may contribute to the steatosis-reducing activities of CORT118335. The fact that mifepristone in most experiments led to a comparable reduction in food intake excludes this factor as the sole responsible mechanism. In this respect, pair feeding experiments can be of interest, but were not performed as food restriction is intrinsically stressful and would strongly complicate our experimental results. In addition to the strong beneficial effects on the liver, CORT118335 treatment also improved overall metabolic health, which is exemplified by a reduction of body weight and improved glucose tolerance, reflecting increased insulin sensitivity. These effects are not unique to CORT118335, as other selective receptor modulators such as CORT108297 and the GR antagonist mifepristone were shown to have similar metabolic activities (45,46). The robust effect of CORT118335 on liver lipids is distinctive from other GR ligands. Nevertheless, metabolic effects of CORT118335 may be a consequence of reduced hepatic lipid content, thereby improving insulin sensitivity and reducing inflammation (47). As transcriptome analysis showed that CORT118335 was less capable than corticosterone in transrepressing inflammatory pathways, it is unlikely that CORT118335 is a strong anti-inflammatory drug via classical GR-mediated transrepression (48). The effects of CORT118335 on muscle (and bone) catabolism, as apparent from lean mass data, are most likely driven by (partial) GR agonistic actions and will be focus of further investigation.

While extra-hepatic mechanisms may contribute to the effects of CORT118335, several facts argue for a strong direct effect on hepatocytes. Measurements of VLDL-triglyceride production, hepatic LCFA composition and the CORT118335-associated transcriptome were obtained very early after initiation of treatment, even before any substantial (diet-induced) differences in total liver lipid content had developed. In addition, the compound provokes a number of effects that

have been found by specific targeting of liver GR and very short term transcriptional changes (24). The substantial body of data on liver lipids based on targeted GR manipulation also argues against a dominant role of the mineralocorticoid receptor at which CORT118335 acts as a lower affinity antagonist (14). Thus, there are liver-specific effects that are exclusive for CORT118335 and that reduce NAFLD development.

While full GR agonism stimulates and full GR antagonism lowers lipid flux through the liver, neither leads to hepatic lipid depletion. Our transcriptome analysis provides support that the unique combination of partial agonism and antagonism at the GR is responsible for the beneficial liver activities of CORT118335. Corticosterone but not CORT118335 upregulated gene expression of two out of six known fatty acid transport proteins that are related to liver influx: *Cd36/Fat* and *Fatp4*. The involvement of CD36/FAT in liver steatosis has been shown as hepatocyte specific CD36/FAT knockout mice were protected against HFD-induced hepatic lipid accumulation (35).

Besides reducing hepatic triglycerides, CORT118335 also had cholesterol-lowering activity. This effect seems to be the result of enhanced cholesterol efflux (VLDL-production) and, as suggested from our transcriptomics data, a lack of effect on cholesterol biosynthesis pathways (e.g. *Hmgcs1*). Reducing hepatic cholesterol levels, with for example HMG-coA inhibitors (statins), was shown to improve NAFLD and non-alcoholic steatohepatitis and was recently even suggested as a novel therapeutic strategy (49,50).

Selective GR modulation or ‘dissociated signaling’ has been pursued as inflammatory disease treatment for decades (51). Our data establish that it is feasible to use selective GR modulation to target GR-dependent diseases, by interfering with metabolic fluxes – not only in prevention, but also in a reversal setting. Further mechanistic studies on selective receptor modulators will help with understanding and predicting which GR transcriptional coregulators and signaling pathways are involved in pathogenic processes. In itself, CORT118335 forms an interesting lead for future clinical development.

#### **Acknowledgments:**

We gratefully thank Sander van der Zeeuw for valuable assistance with bioinformatic analysis of the RNA sequence data. We would also like to show our gratitude to our colleagues of RenaSci (Nottingham) for conducting mouse experiments that are of great value to the manuscript.

**Funding:** This study was partially funded by Corcept Therapeutics. L.K. was funded with a grant by the Board of Directors of Leiden University Medical Center. K.H. was supported by the European Community’s Seventh Framework Programme (FP7/2007-2013) under grant agreement n 305444 “RD-Connect”.

Corcept Therapeutics, Not Applicable; Board of Directors of Leiden University Medical Center, Lisa L Koorneef; FP7 Ideas: European Research Council  
<http://dx.doi.org/10.13039/100011199>, FP7/2007-2013, Kristina M Hettne

**Corresponding author:** Onno C. Meijer, PhD, Department of Internal Medicine, division of Endocrinology, Leiden University Medical Center, Room C7-44, 2300 RA, Leiden, the Netherlands, Phone: +31-71-5261109, Email: [o.c.meijer@lumc.nl](mailto:o.c.meijer@lumc.nl)

Competing interests:

H.H. and J.B. are employees of Corcept Therapeutics, a pharmaceutical company that develops selective modulators, including CORT118335. K.H. performs paid consultancy for Euretos b.v, a startup that develops knowledge management and discovery services for the life sciences with

the Euretos Knowledge Platform as a marketed product. CORT118335 has been filed a patent (WO2012/129074), on which J.H. and O.M. are co-inventors.

## References

- Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. *J Hepatol*. 2013;58(3):593-608.
- Rinella ME, Sanyal AJ. Management of NAFLD: a stage-based approach. *Nat Rev Gastroenterol Hepatol*. 2016;13(4):196-205.
- Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. *Alimentary pharmacology & therapeutics*. 2011;34(3):274-285.
- Woods CP, Hazlehurst JM, Tomlinson JW. Glucocorticoids and non-alcoholic fatty liver disease. *The Journal of steroid biochemistry and molecular biology*. 2015;154:94-103.
- Hollenberg SM, Weinberger C, Ong ES, Cerelli G, Oro A, Lebo R, Thompson EB, Rosenfeld MG, Evans RM. Primary structure and expression of a functional human glucocorticoid receptor cDNA. *Nature*. 1985;318(6047):635-641.
- Yu CY, Mayba O, Lee JV, Tran J, Harris C, Speed TP, Wang JC. Genome-wide analysis of glucocorticoid receptor binding regions in adipocytes reveal gene network involved in triglyceride homeostasis. *PLoS one*. 2010;5(12):e15188.
- Vegiopoulos A, Herzig S. Glucocorticoids, metabolism and metabolic diseases. *Molecular and cellular endocrinology*. 2007;275(1-2):43-61.
- D'Souza A M, Beaudry JL, Szigiato AA, Trumble SJ, Snook LA, Bonen A, Giacca A, Riddell MC. Consumption of a high-fat diet rapidly exacerbates the development of fatty liver disease that occurs with chronically elevated glucocorticoids. *American journal of physiology Gastrointestinal and liver physiology*. 2012;302(8):G850-863.
- Warrier M, Hinds TD, Jr., Ledford KJ, Cash HA, Patel PR, Bowman TA, Stechschulte LA, Yong W, Shou W, Najjar SM, Sanchez ER. Susceptibility to diet-induced hepatic steatosis and glucocorticoid resistance in FK506-binding protein 52-deficient mice. *Endocrinology*. 2010;151(7):3225-3236.
- Asagami T, Belanoff JK, Azuma J, Blasey CM, Clark RD, Tsao PS. Selective Glucocorticoid Receptor (GR-II) Antagonist Reduces Body Weight Gain in Mice. *J Nutr Metab*. 2011;2011:235389.
- Thiele S, Ziegler N, Tsourdi E, De Bosscher K, Tuckermann JP, Hofbauer LC, Rauner M. Selective glucocorticoid receptor modulation maintains bone mineral density in mice. *J Bone Miner Res*. 2012;27(11):2242-2250.
- Brandish PE, Anderson K, Baltus GA, Bai C, Bungard CJ, Bunting P, Byford A, Chiu CS, Cicmil M, Corcoran H, Euler D, Fisher JE, Gambone C, Hasbun-Manning M, Kuklin N, Landis E, Lifsted TQ, McElwee-Witmer S, McIntosh IS, Meissner RS, Miao J, Mitchell HJ, Musselman A, Schmidt A, Shin J, Szczerba P, Thompson CD, Tribouley C, Vogel RL, Warrier S, Hershey JC. The preclinical efficacy, selectivity and pharmacologic profile of MK-5932, an insulin-sparing selective glucocorticoid receptor modulator. *European journal of pharmacology*. 2014;724:102-111.
- Atucha E, Zalachoras I, van den Heuvel JK, van Weert LT, Melchers D, Mol IM, Belanoff JK, Houtman R, Hunt H, Roozendaal B, Meijer OC. A Mixed Glucocorticoid/Mineralocorticoid Selective Modulator With Dominant Antagonism in the Male Rat Brain. *Endocrinology*. 2015;156(11):4105-4114.

14. Hunt HJ, Ray NC, Hynd G, Sutton J, Sajad M, O'Connor E, Ahmed S, Lockey P, Daly S, Buckley G, Clark RD, Roe R, Blasey C, Belanoff J. Discovery of a novel non-steroidal GR antagonist with in vivo efficacy in the olanzapine-induced weight gain model in the rat. *Bioorganic & medicinal chemistry letters*. 2012;22(24):7376-7380.
15. Zalachoras I, Houtman R, Atucha E, Devos R, Tijssen AM, Hu P, Lockey PM, Datson NA, Belanoff JK, Lucassen PJ, Joels M, de Kloet ER, Roozendaal B, Hunt H, Meijer OC. Differential targeting of brain stress circuits with a selective glucocorticoid receptor modulator. *Proc Natl Acad Sci U S A*. 2013;110(19):7910-7915.
16. Van Klinken JB, van den Berg SA, Havekes LM, Willems Van Dijk K. Estimation of activity related energy expenditure and resting metabolic rate in freely moving mice from indirect calorimetry data. *PloS one*. 2012;7(5):e36162.
17. Redgrave TG, Roberts DC, West CE. Separation of plasma lipoproteins by density-gradient ultracentrifugation. *Analytical biochemistry*. 1975;65(1-2):42-49.
18. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. *Canadian journal of biochemistry and physiology*. 1959;37(8):911-917.
19. Muskiet FA, van Doormaal JJ, Martini IA, Wolthers BG, van der Slik W. Capillary gas chromatographic profiling of total long-chain fatty acids and cholesterol in biological materials. *Journal of chromatography*. 1983;278(2):231-244.
20. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. *Nature methods*. 2012;9(7):671-675.
21. McCarthy DJ, Chen Y, Smyth GK. Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation. *Nucleic acids research*. 2012;40(10):4288-4297.
22. Koorneef LL, Heuvel JKvd, Kroon J, Boon MR, Hoen PACT, Hettne KM, Velde NMvd, Kolenbrander KB, Streefland TCM, Mol IM, Sips HCM, Kielbasa SM, Mei H, Belanoff JK, Pereira AM, Oosterveer MH, Hunt H, Rensen PCN, Meijer OC. Data from: Selective glucocorticoid receptor modulation prevents and reverses non-alcoholic fatty liver disease in male mice. Deposited 24 September 2018. <https://doi.org/10.6084/m9.figshare.7110815>.
23. Shelness GS, Sellers JA. Very-low-density lipoprotein assembly and secretion. *Current opinion in lipidology*. 2001;12(2):151-157.
24. Phuc Le P, Friedman JR, Schug J, Brestelli JE, Parker JB, Bochkis IM, Kaestner KH. Glucocorticoid receptor-dependent gene regulatory networks. *PLoS genetics*. 2005;1(2):e16.
25. Davis AP, Grondin CJ, Johnson RJ, Sciaky D, King BL, McMorran R, Wiegiers J, Wiegiers TC, Mattingly CJ. The Comparative Toxicogenomics Database: update 2017. *Nucleic acids research*. 2017;45(D1):D972-D978.
26. Cerami EG, Gross BE, Demir E, Rodchenkov I, Babur O, Anwar N, Schultz N, Bader GD, Sander C. Pathway Commons, a web resource for biological pathway data. *Nucleic acids research*. 2011;39(Database issue):D685-690.
27. Wingender E. The TRANSFAC project as an example of framework technology that supports the analysis of genomic regulation. *Briefings in bioinformatics*. 2008;9(4):326-332.
28. Orchard S, Ammari M, Aranda B, Breuza L, Briganti L, Broackes-Carter F, Campbell NH, Chavali G, Chen C, del-Toro N, Duesbury M, Dumousseau M, Galeota E, Hinz U, Iannuccelli M, Jagannathan S, Jimenez R, Khadake J, Lagreid A, Licata L, Lovering RC, Meldal B, Melidoni AN, Milagros M, Peluso D, Perfetto L, Porrás P, Raghunath A, Ricard-Blum S, Roehert B, Stutz A, Tognolli M, van Roey K, Cesareni G, Hermjakob H. The MIntAct project--

IntAct as a common curation platform for 11 molecular interaction databases. *Nucleic acids research*. 2014;42(Database issue):D358-363.

29. Chatr-Aryamontri A, Oughtred R, Boucher L, Rust J, Chang C, Kolas NK, O'Donnell L, Oster S, Theesfeld C, Sellam A, Stark C, Breitkreutz BJ, Dolinski K, Tyers M. The BioGRID interaction database: 2017 update. *Nucleic acids research*. 2017;45(D1):D369-D379.
30. Fabregat A, Sidiropoulos K, Garapati P, Gillespie M, Hausmann K, Haw R, Jassal B, Jupe S, Korninger F, McKay S, Matthews L, May B, Milacic M, Rothfels K, Shamovsky V, Webber M, Weiser J, Williams M, Wu G, Stein L, Hermjakob H, D'Eustachio P. The Reactome pathway Knowledgebase. *Nucleic acids research*. 2016;44(D1):D481-487.
31. Milacic M, Haw R, Rothfels K, Wu G, Croft D, Hermjakob H, D'Eustachio P, Stein L. Annotating cancer variants and anti-cancer therapeutics in reactome. *Cancers*. 2012;4(4):1180-1211.
32. Declercq J, Brouwers B, Pruniau VP, Stijnen P, de Faudeur G, Tuand K, Meulemans S, Serneels L, Schraenen A, Schuit F, Creemers JW. Metabolic and Behavioural Phenotypes in Nestin-Cre Mice Are Caused by Hypothalamic Expression of Human Growth Hormone. *PLoS one*. 2015;10(8):e0135502.
33. Yao L, Wang C, Zhang X, Peng L, Liu W, Zhang X, Liu Y, He J, Jiang C, Ai D, Zhu Y. Hyperhomocysteinemia activates the aryl hydrocarbon receptor/CD36 pathway to promote hepatic steatosis in mice. *Hepatology*. 2016;64(1):92-105.
34. Zhou J, Febbraio M, Wada T, Zhai Y, Kuruba R, He J, Lee JH, Khadem S, Ren S, Li S, Silverstein RL, Xie W. Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis. *Gastroenterology*. 2008;134(2):556-567.
35. Wilson CG, Tran JL, Erion DM, Vera NB, Febbraio M, Weiss EJ. Hepatocyte-Specific Disruption of CD36 Attenuates Fatty Liver and Improves Insulin Sensitivity in HFD-Fed Mice. *Endocrinology*. 2016;157(2):570-585.
36. Pinero J, Bravo A, Queralt-Rosinach N, Gutierrez-Sacristan A, Deu-Pons J, Centeno E, Garcia-Garcia J, Sanz F, Furlong LI. DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants. *Nucleic acids research*. 2017;45(D1):D833-D839.
37. Cote I, Ngo Sock ET, Levy E, Lavoie JM. An atherogenic diet decreases liver FXR gene expression and causes severe hepatic steatosis and hepatic cholesterol accumulation: effect of endurance training. *European journal of nutrition*. 2013;52(5):1523-1532.
38. Martin IV, Schmitt J, Minkenberg A, Mertens JC, Stieger B, Mullhaupt B, Geier A. Bile acid retention and activation of endogenous hepatic farnesoid-X-receptor in the pathogenesis of fatty liver disease in ob/ob-mice. *Biological chemistry*. 2010;391(12):1441-1449.
39. Graupera I, Coll M, Pose E, Elia C, Piano S, Sola E, Blaya D, Huelin P, Sole C, Moreira R, de Prada G, Fabrellas N, Juanola A, Morales-Ruiz M, Sancho-Bru P, Villanueva C, Gines P. Adipocyte Fatty-Acid Binding Protein is Overexpressed in Cirrhosis and Correlates with Clinical Outcomes. *Scientific reports*. 2017;7(1):1829.
40. Masetti M, Bianchi G, Gianotti G, Giovagnoli M, Vizioli L, Zorzi V, Rossi V, Forti P, Zoli M. Adipocyte-fatty acid binding protein and non-alcoholic fatty liver disease in the elderly. *Aging clinical and experimental research*. 2014;26(3):241-247.
41. Jeppesen J, Mogensen M, Prats C, Sahlin K, Madsen K, Kiens B. FAT/CD36 is localized in sarcolemma and in vesicle-like structures in subsarcolemma regions but not in mitochondria. *Journal of lipid research*. 2010;51(6):1504-1512.

42. Schaefer CF, Anthony K, Krupa S, Buchoff J, Day M, Hannay T, Buetow KH. PID: the Pathway Interaction Database. *Nucleic acids research*. 2009;37(Database issue):D674-679.
43. van den Beukel JC, Boon MR, Steenbergen J, Rensen PC, Meijer OC, Themmen AP, Grefhorst A. Cold Exposure Partially Corrects Disturbances in Lipid Metabolism in a Male Mouse Model of Glucocorticoid Excess. *Endocrinology*. 2015;156(11):4115-4128.
44. Spiga F, Walker JJ, Terry JR, Lightman SL. HPA axis-rhythms. *Comprehensive Physiology*. 2014;4(3):1273-1298.
45. van den Heuvel JK, Boon MR, van Hengel I, Peschier-van der Put E, van Beek L, van Harmelen V, van Dijk KW, Pereira AM, Hunt H, Belanoff JK, Rensen PC, Meijer OC. Identification of a selective glucocorticoid receptor modulator that prevents both diet-induced obesity and inflammation. *British journal of pharmacology*. 2016;173(11):1793-1804.
46. Mammi C, Marzolla V, Armani A, Feraco A, Antelmi A, Maslak E, Chlopicki S, Cinti F, Hunt H, Fabbri A, Caprio M. A novel combined glucocorticoid-mineralocorticoid receptor selective modulator markedly prevents weight gain and fat mass expansion in mice fed a high-fat diet. *International journal of obesity*. 2016;40(6):964-972.
47. Lonardo A, Lombardini S, Ricchi M, Scaglioni F, Loria P. Review article: hepatic steatosis and insulin resistance. *Alimentary pharmacology & therapeutics*. 2005;22 Suppl 2:64-70.
48. De Bosscher K, Van Craenenbroeck K, Meijer OC, Haegeman G. Selective transrepression versus transactivation mechanisms by glucocorticoid receptor modulators in stress and immune systems. *European journal of pharmacology*. 2008;583(2-3):290-302.
49. Imprialos KP, Stavropoulos K, Doumas M, Skalkou A, Zografou I, Athyros VG. The potential role of statins in treating liver disease. *Expert Rev Gastroenterol Hepatol*. 2018;12(4):331-339.
50. Seif El-Din SH, El-Lakkany NM, El-Naggar AA, Hammam OA, Abd El-Latif HA, Ain-Shoka AA, Ebeid FA. Effects of rosuvastatin and/or beta-carotene on non-alcoholic fatty liver in rats. *Res Pharm Sci*. 2015;10(4):275-287.
51. Sundahl N, Bridelance J, Libert C, De Bosscher K, Beck IM. Selective glucocorticoid receptor modulation: New directions with non-steroidal scaffolds. *Pharmacology & therapeutics*. 2015;152:28-41.

**Fig. 1 CORT118335 prevents and reverses hepatic lipid accumulation.** In a preventive setting, mice received 10% fructose water and a high-fat diet (HFD) containing vehicle or CORT118335 (C118) for three weeks (n=8 per group). A-C) C118 reduced body weight, fat mass and lean mass. D-G) C118 additionally reduced caloric intake, energy expenditure and fat oxidation but not carbohydrate oxidation in week 1. H) C118 increased intravenous glucose tolerance in week 2; glucose levels shown are corrected for baseline. I) C118 strongly reduced hepatic triglycerides and cholesterol in week 2. J) In a reversal setting, mice received low-fat diet (LFD), 10% fructose water and a HFD supplemented with vehicle or C118, or HFD for three weeks followed by HFD supplemented with C118 for three weeks (Reversal or Rev, n=8 per group). K-L) C118 reduced body weight, and fully normalized hepatic triglycerides and cholesterol. M) Representative images of hepatic lipid staining using oil red O. In a more severe NAFLD model, mice received HFD for 16 weeks after which treatment with vehicle or C118 (5 and 30 mg/kg/day) was started. N-O) C118 dose-dependently reduced hepatic triglycerides but not cholesterol. ~ = p<0.1 vs HFD 3 wks; \* = p<0.05, \*\* = p<0.01, \*\*\* = p<0.001 vs HFD 3 wks; \$ = p<0.05, \$\$\$ p<0.001 vs HFD 6 wks; #### = p<0.001 vs LFD.


**Fig. 2. CORT118335 increases hepatic VLDL-triglyceride production and decreases long-chain fatty acid uptake.** A) In a preventive setting, mice received 10% fructose water with high-fat diet (HFD) containing vehicle or CORT118335 (C118). C118 selectively affected expression of genes related to hepatic lipid but not to glucose metabolism after three weeks (n=8 per group). B-C) VLDL production measurements after two days of C118 or vehicle treatment in mice that received HFD for 2.5 weeks (n=8 per group) showed that C118 increased plasma triglyceride accumulation after inhibition of tissue lipoprotein lipase, i.e. VLDL-TG production rate. D-E) The amount of produced VLDL particles was not different as measured with Tran<sup>35</sup>S labelling of apolipoproteins, CORT118335 rather increased the amount of TG per apoB. F) Long-chain fatty acid composition indicated C118 reduced fatty acid uptake as compared to corticosterone treatment (C18:2w6), but did not alter de novo lipogenesis (C20:4w6). Mice received low-fat diet (LFD), high-fat diet (HFD) supplemented with vehicle, C118 or corticosterone for two days (n=4 per group) and in G) respective diets. \* = p<0.05, \*\* = p<0.01, \*\*\* = p<0.001 vs HFD; # = p<0.05, ## = p<0.01, ### = p<0.001 vs LFD; \$(~) = p<0.01, \$= p<0.05 vs corticosterone.


**Fig. 3 CORT118335 is a selective GR modulator with predominantly partial agonistic properties on hepatic gene expression.** RNA sequence analysis was performed on livers of mice that received low-fat diet (LFD), 10% fructose water and a high-fat diet (HFD) supplemented with vehicle, CORT118335 (C118) or corticosterone (CORT) for two days (n=4 per group). A) Heatmap of clustered Z-scores based on the fit to the distribution of normalized gene counts across all conditions for genes that showed significant (P<0.00001) differences between any of the groups B) The number of differentially expressed genes in four different comparisons, 1) HFD vs LFD diet, 2) CORT vs HFD, 3) C118 vs HFD and 4) CORT vs C118, reveal that C118 regulates half as many genes as CORT. C) Venn diagram of overlap of up- and downregulated genes between different comparisons. D) The slope of the average log fold change induction by C118 versus CORT indicates an intrinsic efficacy of 0.65 for most genes, but one that is substantially lower for some genes.


**Fig. 4 Corticosterone, but not CORT118335, upregulates expression of genes involved in hepatic fatty acid uptake.** RNA sequence analysis was performed on livers of mice that received low-fat diet (LFD), 10% fructose water and a high-fat diet (HFD) supplemented with vehicle, CORT118335 (C118) or corticosterone (CORT) for two days (n=4 per group). A) Pathway analysis on differentially expressed genes in the CORT vs C118 comparison indicated that corticosterone regulated lipid metabolism-related genes stronger than C118 in a HFD context. B) Relationships between *upregulated* genes within the 'Metabolism of lipids and lipoprotein' pathway and 'fatty liver', '*Nr3c1*' (glucocorticoid receptor gene), and 'lipid transport'. C) Hepatic expression of candidate genes.

**Fig. 5 Graphical abstract**











A

Pathway name	Number of genes	P-value
Metabolism of lipids and lipoproteins	41	5.99E-17
Cholesterol biosynthetic process	14	3.35E-14
Superpathway of cholesterol biosynthesis	11	6.03E-13
Biological oxidations	20	5.22E-12
Phase 1 - functionalization of compounds	14	7.55E-11


B



C



ADVANCE ARTICLE



ADVANCE ARTICLE